Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney, Australia, raised £6m in Series A venture financing.
The round was led by new investor Imperial Innovations plc (AIM IVO) with participation from Australian founding investor the Medical Research Commercialisation Fund (MRCF).
The company, which is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK, intends to use the funds to advance its drug discovery program, expand the management team and recruit a microbiology team.
Co-founded by Professor Ian Charles and Dr Dagmar Alber, Auspherix has discovered a new class of antibacterials which show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential. The company aims to progress its novel class of antibacterials through lead optimization to final candidate selection within the next two years.